Earnings
Merck & Co. Beats Expectations in Q3 2025, Lifts Full-Year Forecast
Merck reported Q3 2025 revenue of $17.3 billion and adjusted EPS of $2.58, both above expectations, and raised its full-year outlook.
Total Stories
9
News
MRK
Section
MRK
Earnings
Earnings Update: Merck, PepsiCo, and Eaton Release Q4 Results
Merck, PepsiCo, and Eaton Corporation have unveiled their earnings for the fourth quarter of 2025, showcasing their performance against market expectations.
Earnings
Merck & Co., Inc. Reports Mixed Second-Quarter 2025 Results
Merck's second-quarter performance showed a slight decline in sales compared to the previous year.
Earnings
Merck & Co. (MRK) Reports Better than Expected Results for First-Quarter 2025
Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments.
International
Merk’s Stock Dips as Trump Tariff Plans Now Threaten Pharma Trade
President Trump's proposed tariffs on imported pharmaceuticals could significantly impact global trade.
Market Analysis
Merck’s Stock Rises Amid New Cancer Treatment Drug Breakthrough
MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving treatment time.
Earnings
Merck Reports Mixed Q4: Beats Revenue, Short on EPS Expectations
Despite falling short of anticipated non-GAAP EPS at $1.72, Merck's revenue exceeded expectations.
Earnings
Merck (MRK) Reports Strong Sales Growth in Q3 2024, Beating Market Expectations
Merck's third-quarter financial performance in 2024 showcased robust worldwide sales growth of 4%, reaching $16.7 billion.
Market Analysis
Big Pharma Stocks: Who’s Leading the Race and Who’s Slipping?
Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY.